Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Rosetta Genomics's Debt-to-Equity or its related term are showing as below:
ROSGQ's Debt-to-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.33 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Rosetta Genomics Debt-to-Equity Related Terms
Rosetta Genomics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Rosetta Genomics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROSGQ vs TEAR, IDTA, ABMC: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Rosetta Genomics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rosetta Genomics Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Rosetta Genomics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rosetta Genomics (ROSGQ) has a Debt-to-Equity of 2.23 as of Jun. 2017. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Debt-to-Equity too high?
Rosetta Genomics' current Debt-to-Equity is 2.23. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Rosetta Genomics' value of 2.23 is 575.8% above this industry median.
How does Rosetta Genomics' Debt-to-Equity compare to TEAR and IDTA?
Rosetta Genomics' Debt-to-Equity of 2.23 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Debt-to-Equity is 0.33. Rosetta Genomics' value of 2.23 is 575.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 182 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rosetta Genomics's current Debt-to-Equity of 2.23 is 575.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Debt-to-Equity is 2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Debt-to-Equity of 2.23. The current Debt-to-Equity is 2.23 and 575.8% above the Medical Diagnostics & Research industry median of 0.33. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Debt-to-Equity is 2.23 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROSGQ has been successfully added to your 
